EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 >= 50%

Abstract

ESMO Immuno-Oncology Congress -- DEC 13-16, 2018 -- Geneva, SWITZERLANDWOS: 000459294800115…European Soc Med Oncol, Japanese Soc Med OncolRegeneron Pharmaceutical Inc.; SanofiRegeneron Pharmaceutical Inc. and Sanofi